The Russian Ministry of Health has authorised the use of a single-dose Covid-19 vaccine, Sputnik Light, in Russia. The vaccine, which is the first component of the Gamaleya Institute’s Sputnik V jab, showed 79.4% efficacy from four weeks after administration, according to data from a Phase I/II trial. It also demonstrated the development of virus neutralising antibodies in 91.67% of people 28 days after administration.

The vaccine alliance Gavi has signed an advance purchase agreement with biotech firm Novavax to buy 350 million doses of the company’s Covid-19 vaccine candidate NVX-CoV2373. Gavi secured the agreement on behalf of the COVAX facility and the vaccine delivery will start in Q3 2021, after Novavax receives regulatory approvals. The vaccine will be delivered to both high-income and upper-middle-income countries participating in the COVAX facility, along with 92 lower-income nations in accordance with the Gavi COVAX Advance Market Commitment (AMC).

Biopharma company Trevena’s novel AT1 receptor selective agonist TRRV027 has been chosen for an NIH ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial in Covid-19 patients. The trial, ACTIV-4d RAAS, is being coordinated by Vanderbilt University Medical Center and will study treatments targeting the renin-angiotensin-aldosterone system (RAAS) and ascertain if they can prevent progression of disease or death among hospitalised Covid-19 patients. TRRV027 fights disruption within the RAAS by binding to and rebalancing AT1 receptor activation and blocking the pathways that cause lung damage and blood clotting.